BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00261-2] [Reference Citation Analysis]
2 Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:903-13. [PMID: 34555346 DOI: 10.1016/S2468-1253(21)00308-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Kahl S. Die Rolle der nicht-alkoholischen Fettlebererkrankung für den gewebespezifischen Energiestoffwechsel und die Insulinsensitivität vor und nach Adipositaschirurgie – Hans-Christian-Hagedorn-Projektförderung 2021 – eine Kurzübersicht der Geförderten Sabine Kahl. Diabetologie und Stoffwechsel 2021;16:480-1. [DOI: 10.1055/a-1664-5206] [Reference Citation Analysis]
4 Hashimoto Y, Hamaguchi M, Okamura T, Nakanishi N, Obora A, Kojima T, Fukui M. Metabolic associated fatty liver disease is a risk factor for chronic kidney disease. J Diabetes Investig 2021. [PMID: 34561962 DOI: 10.1111/jdi.13678] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bi Y, Guo X, Zhang M, Zhu K, Shi C, Fan B, Wu Y, Yang Z, Ji G. Bone marrow derived-mesenchymal stem cell improves diabetes-associated fatty liver via mitochondria transformation in mice. Stem Cell Res Ther 2021;12:602. [PMID: 34895322 DOI: 10.1186/s13287-021-02663-5] [Reference Citation Analysis]
6 Ahmed H, Umar MI, Imran S, Javaid F, Syed SK, Riaz R, Hassan W. TGF-β1 signaling can worsen NAFLD with liver fibrosis backdrop. Exp Mol Pathol 2021;124:104733. [PMID: 34914973 DOI: 10.1016/j.yexmp.2021.104733] [Reference Citation Analysis]
7 Cardoso CRL, Villela-Nogueira CA, Leite NC, Salles GF. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study. Cardiovasc Diabetol 2021;20:193. [PMID: 34560854 DOI: 10.1186/s12933-021-01388-2] [Reference Citation Analysis]
8 Kahl S, Pützer J, Roden M. Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis. Semin Liver Dis 2021. [PMID: 34289506 DOI: 10.1055/s-0041-1732354] [Reference Citation Analysis]
9 Hu C, Zhuang X, Zhang J, Wang T, Du S, Wang J, Peng X, Cao Q, Zhang M, Jiang Y. Serum Metabolomics in Patients with Coexisting NAFLD and T2DM Using Liquid Chromatography-Mass Spectrometry. Lab Med 2022:lmab118. [PMID: 35075477 DOI: 10.1093/labmed/lmab118] [Reference Citation Analysis]
10 García-Compeán D, Orsi E, Nishida T, Kumar R. Glycemic control, the unconsidered outcome in the treatment of nonalcoholic fatty liver disease. Ann Hepatol 2022;27:100648. [PMID: 34871785 DOI: 10.1016/j.aohep.2021.100648] [Reference Citation Analysis]
11 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Reference Citation Analysis]
12 Bonsembiante L, Targher G, Maffeis C. Type 2 Diabetes and Dietary Carbohydrate Intake of Adolescents and Young Adults: What Is the Impact of Different Choices? Nutrients 2021;13:3344. [PMID: 34684345 DOI: 10.3390/nu13103344] [Reference Citation Analysis]
13 Roden M. Modulation der Inkretinsekretion durch Probiotika und Diät – Werner-Creutzfeldt-Preis 2021 – eine Kurzübersicht des Preisträgers Michael Roden. Diabetologie und Stoffwechsel 2021;16:465-6. [DOI: 10.1055/a-1664-5096] [Reference Citation Analysis]
14 Xu J, Liu Z, Feng Z, Ren Y, Liu H, Wang Y. Rapid Mining of Novel α-Glucosidase and Lipase Inhibitors from Streptomyces sp. HO1518 Using UPLC-QTOF-MS/MS. Marine Drugs 2022;20:189. [DOI: 10.3390/md20030189] [Reference Citation Analysis]
15 Li J, Qi J, Tang Y, Liu H, Zhou K, Dai Z, Yuan L, Sun C. A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p/miR-320a and ABCA1/CPT1 axis. J Nanobiotechnology 2021;19:363. [PMID: 34789275 DOI: 10.1186/s12951-021-01108-8] [Reference Citation Analysis]
16 Park J, Kim G, Kim B, Han K, Kwon SY, Park SH, Lee Y, Jin S, Kim JH. The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol 2022;21. [DOI: 10.1186/s12933-022-01483-y] [Reference Citation Analysis]
17 Martin A, Lang S, Goeser T, Demir M, Steffen HM, Kasper P. Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. Curr Atheroscler Rep 2022. [PMID: 35507279 DOI: 10.1007/s11883-022-01028-4] [Reference Citation Analysis]
18 Chen Y, Lian C, Sun Q, Wang T, Liu Y, Ye J, Gao L, Yang Y, Liu S, Shen Z, Liu Y. Ramulus Mori (Sangzhi) Alkaloids Alleviate High-Fat Diet-Induced Obesity and Nonalcoholic Fatty Liver Disease in Mice. Antioxidants 2022;11:905. [DOI: 10.3390/antiox11050905] [Reference Citation Analysis]
19 Zou ZY, Ren TY, Fan JG. Multidisciplinary participation: The key to a cure for non-alcoholic fatty liver disease. J Dig Dis 2021. [PMID: 34697893 DOI: 10.1111/1751-2980.13060] [Reference Citation Analysis]
20 Li L, Wang H, Yao Y, Cao J, Jiang Z, Yan W, Chu X, Li Q, Lu M, Ma H. The sex steroid precursor dehydroepiandrosterone prevents nonalcoholic steatohepatitis by activating the AMPK pathway mediated by GPR30. Redox Biol 2021;48:102187. [PMID: 34781165 DOI: 10.1016/j.redox.2021.102187] [Reference Citation Analysis]
21 Rojas YAO, Cuellar CLV, Barrón KMA, Verdugo JPA, Miranda AL. Non-alcoholic Fatty Liver Disease prevalence in Latin America: A systematic review and meta-analysis. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100706] [Reference Citation Analysis]
22 Mertens J, De Block C, Spinhoven M, Driessen A, Francque SM, Kwanten WJ. Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy. Front Pharmacol 2021;12:768576. [PMID: 34759828 DOI: 10.3389/fphar.2021.768576] [Reference Citation Analysis]
23 Lee A, Yang M, Lee Y, Yang T, Wang C, Wang C. Gallic Acid Improves Diabetic Steatosis by Downregulating MicroRNA-34a-5p through Targeting NFE2L2 Expression in High-Fat Diet-Fed db/db Mice. Antioxidants 2022;11:92. [DOI: 10.3390/antiox11010092] [Reference Citation Analysis]
24 Opazo-ríos L, Soto-catalán M, Lázaro I, Sala-vila A, Jiménez-castilla L, Orejudo M, Moreno JA, Egido J, Mas-fontao S. Meta-Inflammation and De Novo Lipogenesis Markers Are Involved in Metabolic Associated Fatty Liver Disease Progression in BTBR ob/ob Mice. IJMS 2022;23:3965. [DOI: 10.3390/ijms23073965] [Reference Citation Analysis]
25 Padda J, Khalid K, Khedr A, Tasnim F, Al-Ewaidat OA, Cooper AC, Jean-Charles G. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus 2021;13:e17321. [PMID: 34557367 DOI: 10.7759/cureus.17321] [Reference Citation Analysis]
26 Georgiev A, Granata C, Roden M. The role of mitochondria in the pathophysiology and treatment of common metabolic diseases in humans. Am J Physiol Cell Physiol 2022. [PMID: 35508191 DOI: 10.1152/ajpcell.00035.2022] [Reference Citation Analysis]
27 Duan X, Wang W, Pan Q, Guo L. Type 2 Diabetes Mellitus Intersects With Pancreatic Cancer Diagnosis and Development. Front Oncol 2021;11:730038. [PMID: 34485159 DOI: 10.3389/fonc.2021.730038] [Reference Citation Analysis]
28 Spearman CW, Abdo A, Ambali A, Awuku YA, Kassianides C, Lesi OA, Ndomondo-Sigonda M, Onyekwere CA, Rwegasha J, Shewaye AB, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol 2021;6:1047-56. [PMID: 34508669 DOI: 10.1016/S2468-1253(21)00296-X] [Reference Citation Analysis]
29 Niu H, Zhou Y. Nonlinear Relationship Between AST-to-ALT Ratio and the Incidence of Type 2 Diabetes Mellitus: A Follow-Up Study. Int J Gen Med 2021;14:8373-82. [PMID: 34819745 DOI: 10.2147/IJGM.S341790] [Reference Citation Analysis]
30 Thomas MC. The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes. Metabolism 2021;128:154961. [PMID: 34958818 DOI: 10.1016/j.metabol.2021.154961] [Reference Citation Analysis]
31 Wu H, Hu D, Li Q, Wang C, Zhu X, Li W, Chen B, Ji P, Huang K, Huang A, Huang J, Dimitrov DS, Wu Y, Ying T. Half-life extension enhances drug efficacy in adeno-associated virus delivered gene therapy. Engineering 2022. [DOI: 10.1016/j.eng.2022.02.009] [Reference Citation Analysis]